A national perioperative platform trial to improve outcomes for surgical patients (PROTECT)

Submission date	Recruitment status Recruiting	Prospectively registered		
20/06/2025		[X] Protocol		
Registration date	Overall study status Ongoing Condition category Surgery	Statistical analysis plan		
23/06/2025		Results		
Last Edited		Individual participant data		
17/12/2025		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

Clinical implementation of new treatments requires evidence from clinical trials. Traditional clinical trials compare two groups: a treatment group and a control group. However, traditional trials are time-consuming and expensive, often taking a long time to set-up, open new centres and start enrolling patients. This delays implementation of new treatments. Platform trials offer a new approach that was used very successfully during the pandemic. Instead of comparing one treatment group to one control group, platform trials compare multiple treatment groups to one control group. Once established, platforms continue to run, with new treatments added as they become available. This reduces the overall number of patients required and reduces the time and cost of setting up a new trial, which makes platform trials a very efficient way to test new treatments. Our aim is to establish a national platform trial for surgical patients is urgently needed.

Who can participate?

Patients aged 18 years and over being treated in a surgical care pathway.

What does the study involve?

This is a trial designed to test multiple research questions for patients undergoing surgery, or within a surgical care pathway. Patient eligibility will be evaluated separately for each research question and they will be offered the opportunity to take part in any or all of the studies for which they are eligible.

For participants who enrol in the PROTECT platform only, a common outcome dataset will be collected at 30 days and 90 days after surgery about their health and well-being. In addition, longer-term outcomes may be collected using national NHS databases including Hospital Episode Statistics or the equivalent databases in Wales, Scotland and Northern Ireland, and Civil Registration Data.

What are the possible benefits and risks of participating?
Participants may not benefit directly from taking part in this study. By taking part in studies

looking at new ways to improve the care they will receive and by allowing the research team to collect information about their healthcare, we hope to improve the health outcomes for surgical patients in the future.

Where is the study run from?
Surgical services of participating hospitals (UK)

When is the study starting and how long is it expected to run for? January 2025 to December 2034

Who is funding the study?

- 1. Barts Charity (G-002514)
- 2. Academy of Medical Science (SGL029\1104)
- 3. British Journal of Anaesthesia (WKR0-2023-0016)

Who is the main contact?

- 1. Priyanthi Dias (p.dias@qmul.ac.uk)
- 2. Salma Begum (salma2.begum@qmul.ac.uk)

Contact information

Type(s)

Public

Contact name

Dr Priyanthi Dias

ORCID ID

https://orcid.org/0000-0003-1740-6165

Contact details

ACCU Research Offices 4th Floor, Office 14 Royal London Hospital Whitechapel London United Kingdom E1 1FR +44 20 3594 0349 p.dias@qmul.ac.uk

Type(s)

Scientific, Principal investigator

Contact name

Dr Tom Abbott

ORCID ID

https://orcid.org/0000-0002-8664-3001

Contact details

ACCU Research Offices 4th Floor, Office 14 Royal London Hospital Whitechapel London United Kingdom E1 1FR +44 20 3594 0349 t.abbott@gmul.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

353122

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

A national perioperative platform trial to improve outcomes for surgical patients (PROTECT)

Acronym

PROTECT

Study objectives

To establish a research and governance infrastructure for the efficient delivery of a suite of surgical and/or perioperative care comparisons to improve outcomes for patients undergoing surgery.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 03/02/2025, London - South East Research Ethics Committee (2 Redman Place, London, E20 1JQ, United Kingdom; +44 207 104 8222; londonsoutheast.rec@hra.nhs.uk), ref: 25 /LO/0043

Study design

This is a multi-centre multi-factorial platform trial designed to test multiple comparisons (research questions) for patients undergoing surgery, or within a surgical care pathway. Patient eligibility will be evaluated for the platform (master protocol) and for each comparison (protocol appendix). Patients enrolled in the PROTECT platform will be offered the opportunity to take

part in any and/or all of the comparisons for which they are eligible. Patients can be enrolled in the platform (master protocol) only or the platform (master protocol) plus one or more comparison(s). Comparisons may be contemporaneous or distributed throughout the surgical care pathway. As new comparisons are added to the platform, they will be assigned a comparison-specific acronym suffix (e.g. PROTECT-AEGIS, etc.), and the comparison-specific trial methodology and delivery will be described in separate appendices to this master protocol document. Each comparison will be added as an individual submission to the relevant regulatory authorities. Amendments made to the master protocol will apply to all appendices. Amendments to an appendix describing an individual comparison(s) will only be relevant to that appendix.

The PROTECT master protocol is the over-arching protocol which describes the common trial design, delivery and data sets, as well as trial governance procedures common to all comparisons within the platform. Where additional procedures are required, specific to a comparison, for example the collection of additional safety data, these will be described in the appendix for that comparison. The individual appendices are not co-dependent and each will have a separate start and end date. Appendices to the PROTECT master protocol will be added and/or removed throughout the course of the programme. Analyses will be conducted on locked comparison specific datasets and published without compromising the integrity of ongoing platform comparisons. Each individual comparison will have a lead investigator listed in the comparison appendix. Participants enrolled into PROTECT will fall into one or more of the below study categories depending on the eligibility criteria and the journey of their care pathway:

- PROTECT platform
- Non-interventional (non-randomised) studies
- Interventional studies that do not involve Investigational Medicinal Products (IMPs)
- Interventional studies that involve an IMP

Primary study design

Interventional

Study type(s)

Efficacy, Quality of life, Treatment

Health condition(s) or problem(s) studied

All adult patients (≥18 years) being treated within a surgical care pathway at the recruitment sites will be eligible for the trial.

Interventions

A common outcome dataset will be collected for all patients at 30 days and 90 days after surgery. In addition, longer-term outcomes may be collected using routinely collected data (for example Hospital Episode Statistics (HES) and Civil Registration data) up until the last follow up time-point for the participant according to the nature of the groups in which they are enrolled in. Where applicable, primary and secondary outcomes will be described in full in the relevant appendix. Additionally, for CTIMPs, depending on the risk and status of the investigations, part of the objectives will be to collect safety endpoints.

Intervention Type

Other

Primary outcome(s)

Current primary outcome(s) as of 17/12/2025:

- 1. Mortality at one year after surgery.
- 2. Longitudinal mortality, complications and health resource use until the closure of the PROTECT platform.

Previous primary outcome(s):

Measured using patient records:

- 1. Complications within 30 days after surgery
- 2. Days alive and at home at 30 and 90 days after surgery
- 3. Mortality at 30 and 90 days and one year after surgery
- 4. Health-related quality of Life (EQ-5D-5L) at 30 and 90 days after surgery
- 5. Duration of primary hospital admission up to 90 days after surgery
- 6. Re-admission to hospital within 90 days of surgery

Key secondary outcome(s))

There are no secondary outcome measures

Completion date

01/01/2035

Eligibility

Key inclusion criteria

All adult patients (≥18 years) being treated within a surgical care pathway at the recruitment sites will be eligible for the trial.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

Inability or refusal to provide informed consent.

Date of first enrolment 01/01/2025

Date of final enrolment 01/01/2035

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre Barts Health NHS Trust

The Royal London Hospital 80 Newark Street London England E1 2ES

Study participating centre Plymouth Hospitals NHS Trust

Derriford Hospital Derriford Road Crownhill Plymouth England PL6 8DH

Study participating centre The Royal Marsden Hospital

Fulham Road London England SW3 6JJ

Study participating centre University Hospitals Birmingham NHS Foundation Trust

Queen Elizabeth Hospital Mindelsohn Way Edgbaston Birmingham England B15 2GW

Study participating centre

University Hospital Southampton NHS Foundation Trust

Southampton General Hospital Tremona Road Southampton England SO16 6YD

Study participating centre Croydon Health Services NHS Trust

Croydon University Hospital 530 London Road Thornton Heath England CR7 7YE

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital Freeman Road High Heaton Newcastle upon Tyne England NE7 7DN

Study participating centre Leeds Teaching Hospitals NHS Trust

St. James's University Hospital
Beckett Street
Leeds
England
LS9 7TF

Study participating centre Barking, Havering and Redbridge University Hospitals NHS Trust

Queens Hospital Rom Valley Way Romford England RM7 0AG

Study participating centre NHS National Waiting Times Centre Board

Agamemnon Street Clydebank Scotland G81 4DY

Study participating centre NHS Grampian

Summerfield House 2 Eday Road Aberdeen Scotland AB15 6RE

Study participating centre Surrey and Sussex Healthcare NHS Trust

Trust Headquarters
East Surrey Hospital
Canada Avenue
Redhill
England
RH1 5RH

Study participating centre Manchester University NHS Foundation Trust

Cobbett House Oxford Road Manchester England M13 9WL

Study participating centre South Tyneside and Sunderland NHS Foundation Trust

Sunderland Royal Hospital Kayll Road Sunderland England SR4 7TP

Study participating centre Cardiff and Vale University Health Board

University Hospital of Wales Heath Park Cardiff Wales CF14 4XW

Study participating centre North Bristol NHS Foundation Trust

Southmead Hospital Southmead Road Bristol England BS10 5NB

Study participating centre Liverpool University Hospitals NHS Foundation Trust

Mount Vernon Street Liverpool England L7 8YE

Study participating centre Royal Surrey NHS Foundation Trust

Royal Surrey County Hospital Egerton Road Guildford England GU2 7XX

Study participating centre

York and Scarborough Teaching Hospitals NHS Foundation Trust

York Hospital Wigginton Road York England YO31 8HE

Study participating centre The Dudley Group NHS Foundation Trust

Russells Hall Hospital Pensnett Road Dudley England DY1 2HQ

Sponsor information

Organisation

Queen Mary University of London

ROR

https://ror.org/026zzn846

Funder(s)

Funder type

Charity

Funder Name

Barts Charity

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

British Journal of Anaesthesia

Alternative Name(s)

British Journal of Anaesthesia Ltd, BJA

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Academy of Medical Sciences

Alternative Name(s)

The Academy of Medical Sciences

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Available on request. Data sharing statement to be made available at a later date.

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 2.0	19/06/2025	17/12/2025		Yes
Protocol file	version 3.0	19/06/2025	17/12/2025	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes